Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 13Gliosarcoma 11Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Lung Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Glioma 4Adenocarcinoma, Bronchiolo-Alveolar 4Vaginal Neoplasms 3Oropharyngeal Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Biopsy 6trametinib 2olaparib 2dehydroftorafur 2cobimetinib 2atezolizumab 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Capecitabine 2varlilumab 1tremelimumab 1tofacitinib 1tivozanib 1pevonedistat 1peposertib 1pembrolizumab 1nilotinib 1fludarabine 1durvalumab 1ceralasertib 1binimetinib 1avelumab 1aldesleukin 1Taxes 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cholangiocarcinoma × Radiation × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡